• About
  • Partnerships
  • Challenges
  • Awards
  • Grant Opportunities
  • News

Awards

Grand Challenges is a family of initiatives fostering innovation to solve key global health and development problems. Each initiative is an experiment in the use of challenges to focus innovation on making an impact. Individual challenges address some of the same problems, but from differing perspectives.

20Awards

Showing page 1 out of 2 with 10 results per page.

Challenges: China Tsinghua-GCE
Show Descriptions
Results per page

A Glycan Formula as Diet Additive Against Mosquito-Borne Viral Transmission

Gong Cheng, Tsinghua University (Beijing, China)
Mar 1, 2015

Gong Cheng of Tsinghua University in China will develop a glycan formula as a diet additive that specifically inhibits the lectin-based viral receptors in mosquitos, thereby providing a practical approach against dissemination of multiple mosquito-borne viruses.

Design of HIV-1 Epitope Vaccine Based on a Non-Immune Antibody Library from Healthy Individuals

Qi Zhang, Tsinghua University (Beijing, China)
Mar 1, 2015

Qi Zhang of Tsinghua University in China will identify and characterize antibody germline precursors of broadly neutralizing monocolocal antibodies (bnmAbs) with the ultimate goal to design an HIV-1 vaccine candidate able to stimulate the precursors to develop into protective antibodies in healthy individuals.

Developing Safe and Potent Covalent Drugs (Irreversible Inhibitors) Against Multi-Drug-Resistant Bacteria (MDR Bacteria) and Molecular Mechanism Elucidation with Chemical Probes

Yu Rao, Tsinghua University (Beijing, China)
Mar 1, 2015

Yu Rao of Tsinghua University in China will develop safe and potent covalent drugs (irreversible inhibitors) against multi-drug-resistant bacteria (MDR bacteria) and elucidate their molecular mechanisms with chemical probes.

Elimination of ADE-Induced Dengue Virus Infection by a Novel Reagent DCAF

Shan Feng, Tsinghua University (Beijing, China)
Mar 1, 2015

Shan Feng of Tsinghua University in China will develop a novel reagent called DCAF to eliminate antibody-dependence-enhanced (ADE) Dengue virus infection. DCAF stands for Dual-functional Conjugate of Antigenic peptide and Fc-III tag, which is designed for the blocking of cross-reactive antibodies that can enhance secondary infection of Dengue virus. In the current phase, they will synthesize a group of DCAF molecules to test their binding affinities with the antibodies of Dengue virus 2 and to evaluate whether these molecules can be used to block the ADE process.

Identification and Mechanistic Analysis of Novel Antibacterial Compounds

Xue Liu, Tsinghua University (Beijing, China)
Mar 1, 2015

Xue Liu of Tsinghua University in China will identify antibacterial small molecules against the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) by screening compound libraries that contain compounds with novel chemical scaffolds. They will then use the identified antibacterials as probes to find new targets for antibiotic development. The current data include the discovery of two bacteriocidal compounds with novel scaffold structures.

Specific Targeting of Tuberculosis Rifampicin-Tolerant Populations

Babak Javid, Tsinghua University (Beijing, China)
Mar 1, 2015

Javid, Zhu, and colleagues of Tsinghua University in China have developed a strategy to isolate phenotypically-resistant mycobacteria. They will therefore be able to identify small molecules that are specific for this subpopulation as opposed to the bulk tuberculosis population, which may in turn identify pathways to accelerate TB therapy.

Structural Studies of Enveloped Viruses and Structure-Based Vaccine Design

Ye Xiang, Tsinghua University (Beijing, China)
Mar 1, 2015

Ye Xiang of Tsinghua University in China will study enveloped virus glycoprotein structures as a means to better understand the mechanisms by which enveloped viruses infect their hosts. The results obtained will contribute to the general knowledge of enveloped virus infection and maturation in addition to providing important information for vaccine and viral drug design for enveloped viruses such as HIV.

Show Descriptions
Results per page

Great ideas come from everywhere.

Sign up for email updates of the latest grant opportunities and awards.

View the Grand Challenges partnership network

The Bill & Melinda Gates Foundation is part of the Grand Challenges partnership network. Visit www.grandchallenges.org to view the map of awarded grants across this network and grant opportunities from partners.